Riskpilot← Back to searchSign inGet full accessCERimmune Therapeutics AB
ABActiveOrg 5594623034Erik Dahlbergsgatan 11Research and experimental development on natural sciences and engineering · NACE 7210Est. 20230 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
96.7%
Financial strength
Net profit 2024
SEK -76K
0 employees
| Revenue | SEK 0 | — |
| EBITDA | SEK -76K | — |
| Net profit | SEK -76K | — |
| Total assets | SEK 153K | — |
| Equity | SEK 148K | — |
| Employees | 0 | — |
Legal name
CERimmune Therapeutics AB
Org number
5594623034
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 december 2023
Share capital
SEK 26 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna suppleanten
Company purpose
Bolaget ska bedriva utveckling syftande till kommersiell exploatering av profylax, behandling och diagnostiska tester inom medicin, bland annat neurodegenerativa sjukdomar så som Alzheimers sjukdom, och därmed förenlig verksamhet.
Address
Erik Dahlbergsgatan 11
Email
sara.lorentzon@ventures.gu.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | 0 |
| Staff expenses | — |
| EBITDA | −76 |
| Depreciation & amort. | −0 |
| EBIT | −76 |
| Net financials | — |
| Profit before tax | −76 |
| Tax | −0 |
| Net profit | −76 |
| Item | 2024 |
|---|---|
| Total assets | 153 |
| Equity | 148 |
| Long-term debt | 0 |
| Short-term debt | 5 |
| Total debt | 5 |
EBITDA margin
-7600000.0%
This company
15.8%
Market median
-48101366% vs market
20242024
Equity ratio
96.7%
This company
38.2%
Market median
+153% vs market
20242024
Return on equity
-51.4%
This company
18.4%
Market median
-379% vs market
20242024
Net profit margin
-7600000.0%
This company
8.1%
Market median
-93827260% vs market
20242024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20242024
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20242024
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2024 | |
| Chairman | 2024 | |
| Board of Directors | 2024 | |
| Former (3) | ||
| Board of Directors | 2023 – 2024 | |
| Deputy Board Member | 2023 – 2024 | |
| Deputy Board Member | 2023 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CERimmune Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lorna May Fletcher | Deputy Board Member | 0 companies |
| Sara Johanna Louise Lorentzon | Chairman | 0 companies |
| M H Charlotte Wiberg Larsson | Board of Directors | 0 companies |
| Bengt Andreas Björefeldt | Board of Directors | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |